Follow
catherine orrell
catherine orrell
Professor, Desmond Tutu HIV Centre, University of Cape Town
Verified email at hiv-research.org.za
Title
Cited by
Cited by
Year
Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of …
MA Thompson, MJ Mugavero, KR Amico, VA Cargill, LW Chang, R Gross, ...
Annals of internal medicine 156 (11), 817-833, 2012
7222012
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design
SD Lawn, L Myer, C Orrell, LG Bekker, R Wood
Aids 19 (18), 2141-2148, 2005
4652005
Adherence is not a barrier to successful antiretroviral therapy in South Africa
C Orrell, DR Bangsberg, M Badri, R Wood
Aids 17 (9), 1369-1375, 2003
4652003
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ...
New England Journal of Medicine 384 (11), 1003-1014, 2021
3192021
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial
I Sanne, C Orrell, MP Fox, F Conradie, P Ive, J Zeinecker, M Cornell, ...
The Lancet 376 (9734), 33-40, 2010
3032010
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation
SD Lawn, L Myer, G Harling, C Orrell, LG Bekker, R Wood
Clinical infectious diseases 43 (6), 770-776, 2006
2952006
Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality
MWG Brinkhof, A Boulle, R Weigel, E Messou, C Mathers, C Orrell, ...
PLoS medicine 6 (4), e1000066, 2009
2482009
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non …
ET Overton, G Richmond, G Rizzardini, H Jaeger, C Orrell, F Nagimova, ...
The Lancet 396 (10267), 1994-2005, 2020
2332020
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa
LG Bekker, L Myer, C Orrell, S Lawn, R Wood
South African medical journal 96 (4), 315-320, 2006
2172006
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority …
JM Molina, K Squires, PE Sax, P Cahn, J Lombaard, E DeJesus, MT Lai, ...
The lancet HIV 5 (5), e211-e220, 2018
2092018
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa
K Kranzer, J Zeinecker, P Ginsberg, C Orrell, NN Kalawe, SD Lawn, ...
PloS one 5 (11), e13801, 2010
1982010
Improving antiretroviral therapy adherence in resource‐limited settings at scale: a discussion of interventions and recommendations
JE Haberer, L Sabin, KR Amico, C Orrell, O Galárraga, AC Tsai, ...
African Journal of Reproduction and Gynaecological Endoscopy 20 (1), 2017
1852017
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority …
ENCORE1 Study Group
The Lancet 383 (9927), 1474-1482, 2014
1822014
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited
C Orrell, G Harling, SD Lawn, R Kaplan, M McNally, LG Bekker, R Wood
Antiviral therapy 12 (1), 83-88, 2007
1732007
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort
A Boulle, C Orrell, R Kaplan, G Van Cutsem, M McNally, K Hilderbrand, ...
Antiviral therapy 12 (5), 753-760, 2007
1672007
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared
O Keiser, C Orrell, M Egger, R Wood, MWG Brinkhof, H Furrer, ...
PLoS medicine 5 (7), e148, 2008
1662008
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme
SD Lawn, LG Bekker, L Myer, C Orrell, R Wood
Aids 19 (17), 2050-2052, 2005
1572005
Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa
MD Nglazi, SD Lawn, R Kaplan, K Kranzer, C Orrell, R Wood, LG Bekker
JAIDS Journal of Acquired Immune Deficiency Syndromes 56 (1), e1-e8, 2011
1552011
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa
SD Lawn, F Little, LG Bekker, R Kaplan, E Campbel, C Orrell, R Wood
Aids 23 (3), 335-342, 2009
1552009
Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors
K Kranzer, JJ Lewis, N Ford, J Zeinecker, C Orrell, SD Lawn, LG Bekker, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (3), e17-e23, 2010
1452010
The system can't perform the operation now. Try again later.
Articles 1–20